<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145741</url>
  </required_header>
  <id_info>
    <org_study_id>1280.15</org_study_id>
    <nct_id>NCT02145741</nct_id>
  </id_info>
  <brief_title>Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours</brief_title>
  <official_title>An Open-label Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This open-label dose escalation phase I trial, 1280.15, is with the first administration of&#xD;
      BI 836845 in Japanese patients with various types of advanced solid tumours. The rationale&#xD;
      behind this study is to identify the maximum tolerated dose (MTD) of BI 836845 in Japanese&#xD;
      patients with advanced solid tumours as weekly intravenous administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 11, 2014</start_date>
  <completion_date type="Anticipated">March 18, 2022</completion_date>
  <primary_completion_date type="Actual">July 1, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BI 836845 in Japanese patients with advanced solid tumours (as identified by the number of patients with dose-limiting toxicities(DLTs))</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Xentuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients to receive low, middle, and high doses of Xentuzumab intravenously (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xentuzumab, low dose, every week (qw)</intervention_name>
    <description>Patient to receive low dose of Xentuzumab IV</description>
    <arm_group_label>Xentuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xentuzumab, middle dose, qw</intervention_name>
    <description>Patient to receive middle dose of Xentuzumab IV</description>
    <arm_group_label>Xentuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xentuzumab, high dose, qw</intervention_name>
    <description>Patient to receive high dose of Xentuzumab IV</description>
    <arm_group_label>Xentuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients who meet all of the following inclusion criteria by the judgment of investigator&#xD;
        are eligible to receive the study treatment:&#xD;
&#xD;
          1. Patients with cytologically or histologically confirmed solid tumours that are&#xD;
             refractory to standard therapy, for whom no standard therapy of proven efficacy&#xD;
             exists, or who are not amenable to establish treatment options&#xD;
&#xD;
          2. Age &gt;=20 years old&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2&#xD;
&#xD;
          4. Written informed consent that is consistent with Good Clinical Practice (GCP)&#xD;
             guidelines&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients who apply any of the following exclusion criteria by the judgment of investigator&#xD;
        are not eligible to receive the study treatment:&#xD;
&#xD;
          1. Active infectious disease to be incompatible with the study treatment&#xD;
&#xD;
          2. Patients who do not have sufficient major organ function and meet any of the following&#xD;
             test results at screening period&#xD;
&#xD;
               -  Cardiac left ventricular function with resting ejection fraction &lt;=50% as&#xD;
                  determined by echocardiography (ECHO) or multiple-gated acquisition scan (MUGA)&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1500/µL&#xD;
&#xD;
               -  Platelets &lt;100 000/µL&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 × the upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt;2.5 × ULN&#xD;
                  (in case of known liver metastases, AST and/or ALT &gt;5 × ULN)&#xD;
&#xD;
               -  Creatinine &gt;1.5 × ULN&#xD;
&#xD;
               -  Haemoglobin &lt;9 g/dL&#xD;
&#xD;
               -  HbA1c &gt;=8% and fasting glucose &gt;8.9 mmol/L (&gt;160 mg/dL)&#xD;
&#xD;
          3. Serious illness or concomitant non-oncological disease including severe, acute, or&#xD;
             chronic medical or psychiatric condition, or laboratory abnormality that may&#xD;
             compromise the safety of the patient during the study, affect the patient's ability to&#xD;
             complete the study, or interfere with interpretation of study results considered by&#xD;
             the investigator to be incompatible with the study treatment&#xD;
&#xD;
          4. History of thrombosis (except tumour invading great vessels) within 1 year before&#xD;
             start of study treatment or if concurrent anticoagulation required&#xD;
&#xD;
          5. Patients not recovered from any therapy-related toxicities from previous&#xD;
             chemotherapies, hormonal therapies, immunotherapies, molecular-targeted therapies, or&#xD;
             radiotherapies to Common Terminology Criteria for Adverse Events (CTCAE) grade &lt;=1&#xD;
&#xD;
          6. Patients who have not recovered from any previous surgery and major surgery within the&#xD;
             last 4 weeks before start of study treatment&#xD;
&#xD;
          7. Patients with untreated or symptomatic brain metastases.&#xD;
&#xD;
          8. Patients who have been treated with any of the following within 4 weeks before start&#xD;
             of study treatment: chemotherapies, immunotherapies, radiotherapies (within 2 weeks&#xD;
             before start of study treatment for local palliative radiotherapies for the treatment&#xD;
             of brain metastasis or extremities), biological therapies, molecular-targeted&#xD;
             therapies, hormonal therapies for breast cancer within 2 weeks before start of study&#xD;
             treatment, or treatment with other investigational drugs.&#xD;
&#xD;
          9. Patients who have used any investigational drug within 4 weeks before start of study&#xD;
             treatment or who have planned concomitantly use with the trial.&#xD;
&#xD;
         10. Patients unable to comply with the clinical trial protocol (CTP)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba, Kashiwa</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

